从365亿美元到千亿赛道。撰文丨KV324医药行业药王宝座的归属,天然就是一个激烈争夺的过程。然而,新登基不过两年的Keytruda如此快速地退位,却令很多人始料未及。而新药王,正是礼来的替尔泊肽。2025年Mounjaro与Zepbound合计销售额达到365亿美元,同期司美格鲁肽销售额346亿美元、Keytruda销售额317亿美元,替尔泊肽由此成为全球销售额最高的药物。尽管Keytruda...
Source Link从365亿美元到千亿赛道。撰文丨KV324医药行业药王宝座的归属,天然就是一个激烈争夺的过程。然而,新登基不过两年的Keytruda如此快速地退位,却令很多人始料未及。而新药王,正是礼来的替尔泊肽。2025年Mounjaro与Zepbound合计销售额达到365亿美元,同期司美格鲁肽销售额346亿美元、Keytruda销售额317亿美元,替尔泊肽由此成为全球销售额最高的药物。尽管Keytruda...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.